西罗亚医院接种疫苗后医护人员SARS-CoV-2抗体水平差异的危险因素:一项全国性多中心研究

Infectious Medicine Pub Date : 2022-12-01 DOI:10.1016/j.imj.2022.10.001

Allen Widysanto , Ignatius Bima Prasetya , Tandry Meriyanti , Veli Sungono , Diane Lukito Setiawan , Edy Gunawan , Bayu Adiputra , Jane Olivia Lorens , Theresia Santi , Cindy Meidy Leony Pradhana , Irawan Yusuf , Catherine Gunawan

{"title":"西罗亚医院接种疫苗后医护人员SARS-CoV-2抗体水平差异的危险因素:一项全国性多中心研究","authors":"Allen Widysanto , Ignatius Bima Prasetya , Tandry Meriyanti , Veli Sungono , Diane Lukito Setiawan , Edy Gunawan , Bayu Adiputra , Jane Olivia Lorens , Theresia Santi , Cindy Meidy Leony Pradhana , Irawan Yusuf , Catherine Gunawan","doi":"10.1016/j.imj.2022.10.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Several vaccines have been approved against COVID-19, and 5 have been used in Indonesia. Due to the decrease in antibody levels 3 to 6 months after the second dose of CoronaVac, healthcare workers received the third booster of mRNA vaccine (mRNA-1273) to increase the antibody level. This study aimed to evaluate the risk factors of anti-S-RBD IgG levels differences in healthcare workers.</p></div><div><h3>Methods</h3><p>This study is a retrospective cohort study of 576 healthcare workers without previous SARS-CoV-2 infection who received 2 doses of CoronaVac and the third dose of mRNA-1273 6 months after the second dose. Blood samples were obtained 2nd, 6th, 12th, and 24th weeks after the second dose of CoronaVac vaccine administration, with mRNA-1273 booster on week 20. Quantitative measurements of IgG antibodies were performed with Elecsys Anti-SARS-CoV-2 S immunoassay. We identify the baseline factors predicting post-vaccination antibody titers using univariate and multivariate linear regression analysis.</p></div><div><h3>Results</h3><p>This study comprised 576 participants aged 32 years old, 72.05% female, and 45.84% from high-risk occupation subgroups. The median antibodies titer level on the 2nd, 6th, 12th, and 24th weeks after the second vaccine dose administration were 40.99 u/mL, 42.01 u/mL, 54.78 u/mL, and 23,225 u/mL. Antibody levels trended highest in female and younger age group (20-29 years old).</p></div><div><h3>Conclusions</h3><p>The third dose of vaccine increased the quantitative SARS-CoV-2 spike IgG antibody titers and eliminated differences in antibodies titer by gender.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"1 4","pages":"Pages 229-235"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X22000491/pdfft?md5=443ed53aaec0fad03cb5842622cd848e&pid=1-s2.0-S2772431X22000491-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The risk factors of SARS-CoV-2 antibody level differences in healthcare workers post vaccination in Siloam hospitals: A nationwide multicenter study\",\"authors\":\"Allen Widysanto , Ignatius Bima Prasetya , Tandry Meriyanti , Veli Sungono , Diane Lukito Setiawan , Edy Gunawan , Bayu Adiputra , Jane Olivia Lorens , Theresia Santi , Cindy Meidy Leony Pradhana , Irawan Yusuf , Catherine Gunawan\",\"doi\":\"10.1016/j.imj.2022.10.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Several vaccines have been approved against COVID-19, and 5 have been used in Indonesia. Due to the decrease in antibody levels 3 to 6 months after the second dose of CoronaVac, healthcare workers received the third booster of mRNA vaccine (mRNA-1273) to increase the antibody level. This study aimed to evaluate the risk factors of anti-S-RBD IgG levels differences in healthcare workers.</p></div><div><h3>Methods</h3><p>This study is a retrospective cohort study of 576 healthcare workers without previous SARS-CoV-2 infection who received 2 doses of CoronaVac and the third dose of mRNA-1273 6 months after the second dose. Blood samples were obtained 2nd, 6th, 12th, and 24th weeks after the second dose of CoronaVac vaccine administration, with mRNA-1273 booster on week 20. Quantitative measurements of IgG antibodies were performed with Elecsys Anti-SARS-CoV-2 S immunoassay. We identify the baseline factors predicting post-vaccination antibody titers using univariate and multivariate linear regression analysis.</p></div><div><h3>Results</h3><p>This study comprised 576 participants aged 32 years old, 72.05% female, and 45.84% from high-risk occupation subgroups. The median antibodies titer level on the 2nd, 6th, 12th, and 24th weeks after the second vaccine dose administration were 40.99 u/mL, 42.01 u/mL, 54.78 u/mL, and 23,225 u/mL. Antibody levels trended highest in female and younger age group (20-29 years old).</p></div><div><h3>Conclusions</h3><p>The third dose of vaccine increased the quantitative SARS-CoV-2 spike IgG antibody titers and eliminated differences in antibodies titer by gender.</p></div>\",\"PeriodicalId\":100667,\"journal\":{\"name\":\"Infectious Medicine\",\"volume\":\"1 4\",\"pages\":\"Pages 229-235\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772431X22000491/pdfft?md5=443ed53aaec0fad03cb5842622cd848e&pid=1-s2.0-S2772431X22000491-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772431X22000491\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772431X22000491","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景几种针对新冠肺炎的疫苗已被批准，其中5种已在印度尼西亚使用。由于第二剂CoronaVac后3-6个月抗体水平下降，医护人员接种了第三剂信使核糖核酸疫苗加强针（mRNA-1273）以提高抗体水平。本研究旨在评估医护人员抗S-RBD IgG水平差异的危险因素。方法本研究是对576名既往未感染严重急性呼吸系统综合征冠状病毒2型的医护人员的回顾性队列研究，他们在第二剂疫苗接种6个月后接种了2剂CoronaVac和第三剂mRNA-1273。在第二剂CoronaVac疫苗接种后第2、第6、第12和第24周采集血样，第20周使用mRNA-1273加强剂。IgG抗体的定量测量用Elecsys Anti-SARS-CoV-2S免疫测定法进行。我们使用单变量和多变量线性回归分析来确定预测疫苗接种后抗体滴度的基线因素。结果本研究共有576名参与者，年龄32岁，其中72.05%为女性，45.84%来自高危职业亚组。第二剂疫苗给药后第2、6、12和24周的抗体滴度中位数分别为40.99、42.01、54.78和23225。抗体水平在女性和年轻年龄组（20-29岁）呈最高趋势。结论第三剂疫苗提高了严重急性呼吸系统综合征冠状病毒2型刺突IgG抗体的定量滴度，消除了性别抗体滴度的差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The risk factors of SARS-CoV-2 antibody level differences in healthcare workers post vaccination in Siloam hospitals: A nationwide multicenter study

Background

Several vaccines have been approved against COVID-19, and 5 have been used in Indonesia. Due to the decrease in antibody levels 3 to 6 months after the second dose of CoronaVac, healthcare workers received the third booster of mRNA vaccine (mRNA-1273) to increase the antibody level. This study aimed to evaluate the risk factors of anti-S-RBD IgG levels differences in healthcare workers.

Methods

This study is a retrospective cohort study of 576 healthcare workers without previous SARS-CoV-2 infection who received 2 doses of CoronaVac and the third dose of mRNA-1273 6 months after the second dose. Blood samples were obtained 2nd, 6th, 12th, and 24th weeks after the second dose of CoronaVac vaccine administration, with mRNA-1273 booster on week 20. Quantitative measurements of IgG antibodies were performed with Elecsys Anti-SARS-CoV-2 S immunoassay. We identify the baseline factors predicting post-vaccination antibody titers using univariate and multivariate linear regression analysis.

Results

This study comprised 576 participants aged 32 years old, 72.05% female, and 45.84% from high-risk occupation subgroups. The median antibodies titer level on the 2nd, 6th, 12th, and 24th weeks after the second vaccine dose administration were 40.99 u/mL, 42.01 u/mL, 54.78 u/mL, and 23,225 u/mL. Antibody levels trended highest in female and younger age group (20-29 years old).